In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

被引:44
作者
Traczewski, MM [1 ]
Brown, SD [1 ]
机构
[1] Clin Microbiol Inst Inc, Wilsonville, OR 97070 USA
关键词
D O I
10.1128/AAC.50.2.819-821.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activities of doripenem, imipenem, levofloxacin, piperacillin, ceftazidime, aztreonam, tobramycin, and cefepime were determined for 160 isolates of Pseudomonas aeruginosa (82 from cystic fibrosis [CF] patients) and 34 isolates of Burkholderia cepacia. Doripenem MIC(90)s were lower than those of all other comparative agents against all isolates combined and against all P. aeruginosa isolates. Doripenem was as active as levofloxacin and 2- to 32-fold more active than the other comparative agents against B. cepacia.
引用
收藏
页码:819 / 821
页数:3
相关论文
共 6 条
  • [1] PSEUDOMONAS CEPACIA INFECTION IN CYSTIC-FIBROSIS - AN EMERGING PROBLEM
    ISLES, A
    MACLUSKY, I
    COREY, M
    GOLD, R
    PROBER, C
    FLEMING, P
    LEVISON, H
    [J]. JOURNAL OF PEDIATRICS, 1984, 104 (02) : 206 - 210
  • [2] Burkholderia cepacia - Management issues and new insights
    LiPuma, JJ
    [J]. CLINICS IN CHEST MEDICINE, 1998, 19 (03) : 473 - +
  • [3] *NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L
  • [4] *NAT COMM CLIN LAB, 2003, M100S13 NAT COMM CLI
  • [5] Nosocomial infections in medical intensive care units in the United States
    Richards, MJ
    Edwards, JR
    Culver, DH
    Gaynes, RP
    [J]. CRITICAL CARE MEDICINE, 1999, 27 (05) : 887 - 892
  • [6] Todar K., 2004, Todar's online textbook of bacteriology